Gan and Lee Pharmaceuticals (SHSE:603087) Piotroski F-Score: 6 (As of Sep. 12, 2026) — Near Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603087 Gan and Lee Pharmaceuticals SHSE:603087
90 GF Score
Price ¥66.34
GF Value ¥73.00
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Gan and Lee Pharmaceuticals Piotroski F-Score?

Gan and Lee Pharmaceuticals SHSE:603087 -2.27% 90 Piotroski F-Score is 6 as of Sep. 12, 2026, which is at its 10-year median of 6.00. GuruFocus rates SHSE:603087 with a GF Score™ of 90/100 and a GF Value™ of ¥73.00 (Fairly Valued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Gan and Lee Pharmaceuticals ranks better than 80.64% on this metric.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gan and Lee Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Gan and Lee Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

SHSE:603087' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 6   Max: 7
Current: 6

During the past 13 years, the highest Piotroski F-Score of Gan and Lee Pharmaceuticals was 7. The lowest was 2. And the median was 6.

Gan and Lee Pharmaceuticals  (SHSE:603087) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Gan and Lee Pharmaceuticals Piotroski F-Score Related Terms


Gan and Lee Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Gan and Lee Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Gan and Lee Pharmaceuticals Piotroski F-Score Chart

Gan and Lee Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.00 3.00 7.00 6.00 7.00

Gan and Lee Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.00 7.00 7.00 7.00 6.00

SHSE:603087 vs ISRG, BDX, RMD: Piotroski F-Score Comparison

For the Medical Instruments & Supplies subindustry, Gan and Lee Pharmaceuticals's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gan and Lee Pharmaceuticals Piotroski F-Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Gan and Lee Pharmaceuticals's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Gan and Lee Pharmaceuticals's Piotroski F-Score falls into.


SHSE:603087
90GF Score
Gan and Lee Pharmaceuticals SHSE:603087
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun26) TTM:Last Year (Jun25) TTM:
Net Income was 214.659 + 325.244 + 192.486 + 417.295 = ¥1,150 Mil.
Cash Flow from Operations was 233.41 + 302.315 + 171.674 + 260.648 = ¥968 Mil.
Revenue was 980.243 + 1005.108 + 878.109 + 1344.913 = ¥4,208 Mil.
Gross Profit was 745.37 + 751.906 + 654.707 + 993.121 = ¥3,145 Mil.
Average Total Assets from the begining of this year (Jun25)
to the end of this year (Jun26) was
(11877.796 + 12142.758 + 12627.043 + 12679.783 + 12762.003) / 5 = ¥12417.8766 Mil.
Total Assets at the begining of this year (Jun25) was ¥11,878 Mil.
Long-Term Debt & Capital Lease Obligation was ¥2 Mil.
Total Current Assets was ¥5,896 Mil.
Total Current Liabilities was ¥853 Mil.
Net Income was 208.361 + 107.399 + 311.919 + 291.762 = ¥919 Mil.

Revenue was 930.113 + 800.342 + 984.867 + 1081.928 = ¥3,797 Mil.
Gross Profit was 725.971 + 587.077 + 755.958 + 819.961 = ¥2,889 Mil.
Average Total Assets from the begining of last year (Jun24)
to the end of last year (Jun25) was
(11952.557 + 12221.621 + 12042.916 + 12284.435 + 11877.796) / 5 = ¥12075.865 Mil.
Total Assets at the begining of last year (Jun24) was ¥11,953 Mil.
Long-Term Debt & Capital Lease Obligation was ¥3 Mil.
Total Current Assets was ¥3,966 Mil.
Total Current Liabilities was ¥735 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gan and Lee Pharmaceuticals's current Net Income (TTM) was 1,150. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Gan and Lee Pharmaceuticals's current Cash Flow from Operations (TTM) was 968. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun25)
=1149.684/11877.796
=0.0967927

ROA (Last Year)=Net Income/Total Assets (Jun24)
=919.441/11952.557
=0.07692421

Gan and Lee Pharmaceuticals's return on assets of this year was 0.0967927. Gan and Lee Pharmaceuticals's return on assets of last year was 0.07692421. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Gan and Lee Pharmaceuticals's current Net Income (TTM) was 1,150. Gan and Lee Pharmaceuticals's current Cash Flow from Operations (TTM) was 968. ==> 968 <= 1,150 ==> CFROA <= ROA ==> Score 0.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun25 to Jun26
=2.25/12417.8766
=0.00018119

Gearing (Last Year: Jun25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun24 to Jun25
=2.805/12075.865
=0.00023228

Gan and Lee Pharmaceuticals's gearing of this year was 0.00018119. Gan and Lee Pharmaceuticals's gearing of last year was 0.00023228. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun26)=Total Current Assets/Total Current Liabilities
=5896.466/853.374
=6.90959181

Current Ratio (Last Year: Jun25)=Total Current Assets/Total Current Liabilities
=3966.169/735.07
=5.39563443

Gan and Lee Pharmaceuticals's current ratio of this year was 6.90959181. Gan and Lee Pharmaceuticals's current ratio of last year was 5.39563443. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Gan and Lee Pharmaceuticals's number of shares in issue this year was 600.749. Gan and Lee Pharmaceuticals's number of shares in issue last year was 595.162. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=3145.104/4208.373
=0.7473444

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=2888.967/3797.25
=0.76080506

Gan and Lee Pharmaceuticals's gross margin of this year was 0.7473444. Gan and Lee Pharmaceuticals's gross margin of last year was 0.76080506. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun25)
=4208.373/11877.796
=0.35430588

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun24)
=3797.25/11952.557
=0.31769353

Gan and Lee Pharmaceuticals's asset turnover of this year was 0.35430588. Gan and Lee Pharmaceuticals's asset turnover of last year was 0.31769353. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+0+1+1+0+0+1
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Gan and Lee Pharmaceuticals has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 6 mean?
Gan and Lee Pharmaceuticals (SHSE:603087) has a Piotroski F-Score of 6 as of Sep. 12, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Gan and Lee Pharmaceuticals and its competitors. This is near median its historical median of 6.00. Over the past decade, Gan and Lee Pharmaceuticals' Piotroski F-Score has ranged from 2.00 to 7.00. According to the industry distribution chart, Gan and Lee Pharmaceuticals ranks #158 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 19.4%.
Is Gan and Lee Pharmaceuticals' Piotroski F-Score too high?
Gan and Lee Pharmaceuticals' current Piotroski F-Score of 6 is near median its 10-year median of 6.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 7.00. The Medical Devices & Instruments industry median Piotroski F-Score is 5.00. Gan and Lee Pharmaceuticals' value of 6 is 20% above this industry median. Based on the distribution chart, Gan and Lee Pharmaceuticals ranks #158 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Gan and Lee Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Gan and Lee Pharmaceuticals' Piotroski F-Score compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Gan and Lee Pharmaceuticals ranks #158 out of 816 companies for Piotroski F-Score. This places Gan and Lee Pharmaceuticals in the top 19% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Gan and Lee Pharmaceuticals' value of 6 is 20% above this benchmark. Historically, Gan and Lee Pharmaceuticals' own Piotroski F-Score has ranged from 2.00 to 7.00 over the past decade. While the company's 10-year median is 6.00 vs. the industry median of 5.00, Gan and Lee Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Medical Devices & Instruments company?
The median Piotroski F-Score among Medical Devices & Instruments companies is 5.00, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Gan and Lee Pharmaceuticals's current Piotroski F-Score of 6 is 20% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Gan and Lee Pharmaceuticals and its competitors. For the Medical Devices & Instruments industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Gan and Lee Pharmaceuticals's current Piotroski F-Score is 6, which is near median its own 10-year median of 6.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Gan and Lee Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals (SHSE:603087) is currently considered Fairly Valued. The stock's GF Value™ is ¥73.00, compared to a current price of ¥66.34 — trading 9.1% below its estimated fair value. The current Piotroski F-Score is 6, which is near median its 10-year median of 6.00 and 20% above the Medical Devices & Instruments industry median of 5.00. Gan and Lee Pharmaceuticals' overall GF Score™ is 90/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Gan and Lee Pharmaceuticals (SHSE:603087), the current Piotroski F-Score is 6 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Gan and Lee Pharmaceuticals (SHSE:603087) Overvalued in 2026?

Based on GuruFocus' analysis, Gan and Lee Pharmaceuticals stock appears to be undervalued. The current stock price of ¥66.34 is trading 9.1% below its estimated GF Value™ of ¥73.00. GuruFocus considers Gan and Lee Pharmaceuticals to be Fairly Valued.

Key valuation signals for SHSE:603087:

  • Piotroski F-Score: 6 (near median its 10-year median of 6.00)
  • GF Value™: ¥73.00 vs. price of ¥66.34 (9.1% below fair value)
  • GF Score™: 90/100 with 5 warning signs
  • Industry Position: 20% above the Medical Devices & Instruments median (#158 of 816)

No single metric tells the full story. See the SHSE:603087 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Gan and Lee Pharmaceuticals Business Description

Address No. 8, Nanfengxi 1st Road, Xianxian Town, Tongzhou District, Beijing, CHN, 101109
Gan and Lee Pharmaceuticals is engaged in Research, development, production and sales of recombinant insulin analog APIs and injections.
90GF Score

Get the complete analysis for SHSE:603087

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥66.34
Price
¥73.00
GF Value